Could COPD drug help control blood sugar? new study explores

NCT ID NCT02363335

First seen Jun 26, 2026 · Last updated Jul 29, 2026 · Updated 4 times

Summary

This completed Phase 1 trial studied how two drugs, roflumilast (used for COPD) and sitagliptin (used for diabetes), affect blood sugar and gut hormones in 29 healthy volunteers aged 21-55. Participants received each drug alone, together, or a placebo, then drank a nutritional shake to measure hormone responses. The goal was to understand how these drugs might lower blood sugar, which could lead to new treatments for type 2 diabetes.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
Roflumilast and Sitagliptin
What this could lead to
If successful, this research could point toward new treatments for type 2 diabetes by better understanding how these drugs affect blood sugar and gut hormones.
What could go wrong
This is a small, early-phase study in healthy volunteers, not people with diabetes. The results may not apply to patients or lead to a new treatment.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEALTHY VOLUNTEERS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • National Institute of Aging, Clinical Research Unit

    Baltimore, Maryland, 21224, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.